Virtu Financial LLC Purchases 54,117 Shares of Ocular Therapeutix, Inc. $OCUL

Virtu Financial LLC lifted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 470.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,627 shares of the biopharmaceutical company’s stock after buying an additional 54,117 shares during the period. Virtu Financial LLC’s holdings in Ocular Therapeutix were worth $797,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Millennium Management LLC boosted its position in Ocular Therapeutix by 3,136.1% during the 3rd quarter. Millennium Management LLC now owns 3,855,706 shares of the biopharmaceutical company’s stock worth $45,073,000 after acquiring an additional 3,736,560 shares during the last quarter. Alliancebernstein L.P. raised its holdings in shares of Ocular Therapeutix by 2,003.2% in the third quarter. Alliancebernstein L.P. now owns 3,424,439 shares of the biopharmaceutical company’s stock valued at $40,032,000 after purchasing an additional 3,261,619 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Ocular Therapeutix by 38.5% in the third quarter. Avoro Capital Advisors LLC now owns 10,250,000 shares of the biopharmaceutical company’s stock worth $119,822,000 after purchasing an additional 2,850,000 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Ocular Therapeutix by 26.3% in the fourth quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock worth $140,523,000 after purchasing an additional 2,411,953 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in Ocular Therapeutix by 106.5% during the fourth quarter. Janus Henderson Group PLC now owns 4,229,202 shares of the biopharmaceutical company’s stock worth $51,321,000 after purchasing an additional 2,180,702 shares during the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Insider Activity

In related news, insider Pravin Dugel sold 21,156 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total value of $173,479.20. Following the completion of the sale, the insider directly owned 2,597,170 shares in the company, valued at approximately $21,296,794. This trade represents a 0.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 28,999 shares of company stock valued at $237,792. 3.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target (up from $21.00) on shares of Ocular Therapeutix in a research note on Thursday, June 18th. Needham & Company LLC restated a “buy” rating and set a $18.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, May 5th. William Blair restated an “outperform” rating on shares of Ocular Therapeutix in a report on Monday, March 2nd. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $30.00 target price on shares of Ocular Therapeutix in a research report on Wednesday, May 6th. Finally, Wall Street Zen lowered Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $24.89.

Ocular Therapeutix Price Performance

Shares of OCUL opened at $9.97 on Tuesday. The company has a current ratio of 14.81, a quick ratio of 14.73 and a debt-to-equity ratio of 0.12. The company’s fifty day simple moving average is $9.00 and its 200 day simple moving average is $9.89. Ocular Therapeutix, Inc. has a 1-year low of $6.23 and a 1-year high of $16.44. The company has a market cap of $2.18 billion, a price-to-earnings ratio of -6.83 and a beta of 0.89.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.